No Data
Daily Bull and Bear | Hang Seng Index maintains a volatile market, with a net inflow of 7 million Hong Kong dollars into good warehouses; Innovent Bio rebounds nearly 13%, with warrants rising more than 100%.
On Monday, the Hang Seng Index maintained a volatile market, closing up 0.30% at 20,567.52 points for the day, reaching a high of 20,633.58 and a low of 20,446.26 during the session.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.
A quick overview: Hong Kong stock market bullish and bearish stock list for October is out! Good performance, china-affiliated brokerage stocks continue to party, haitong sec soars 79%; positive restructuring news boosts chongqing iron with a 45% surge.
The Hang Seng Tech Index has experienced a significant drop this month, with a cumulative decline of over 5%; the Hang Seng Index and the A-share Index have fallen by 3.86% and 3.27% respectively.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Market cap evaporated by over 10 billion in a week! Is the innovent bio director's 'clever move' of acquiring international business at low stock prices a bargain or part of a global strategy?
①Innovent Bio director Yu Dechao acquired the equity of the subsidiary Fortvita at the net asset price, without generating a premium based on future development expectations; ②This event has sparked widespread market skepticism, with the company's stock price falling for four consecutive days, during which time the market cap evaporated by over 17 billion Hong Kong dollars; ③The company's recent overseas expansion has not been smooth, with the FDA rejecting the PD-1 product application, and several products have been "cut loss" in a timely manner.
Zheng Da Tianqing's fourth-generation EGFR inhibitor cancer new drug has been approved for clinical use.